101A Multi-Omic Single-Cell Landscape of Cytokine Release Syndrome in Multiple Myeloma Patients after Anti-BCMA CAR-T Cell Therapy 胡永仙，浙江大学医学院附属第一医院 117Discovery of BCL-XL Heterobifunctional Degrader with Potentially Improved Therapeutic Window and Minimal Platelet Toxicity for Hematolog...
曾志勇,福建医科大学附属第一医院 867Safety and Efficacy of Tgrx-678, a Potent BCR-ABL Allosteric Inhibitor in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant/Refractory Chronic Myeloid Leukemia (CML): Preliminary Results of Phase I Study 江倩,北京大学人民医院 869Olverembatinib (HQP1351) De...
2. Capodanno I, Tiribelli M, Miggiano MC, et al. Choice of tyrosine kinase inhibitor and early events during the first year of therapy in newly diagnosed chronic phase chronic myeloid leukemia (CML) patients with concomitant diabetes: a “Campus CML” study. Presented at: 64th ASH Annual ...
Another practice-changer is the a-TREAT trial (Abstract 2) on the effects of tranexamic acid prophylaxis on bleeding outcomes in hematologic malignancy, which was a negative study. Tranexamic acid is frequently used by hematologists prophylactically in patients who have low platelet counts to decrea...
Agarwal, N. 4541 - Real-World Effectiveness of Asciminib in Patients with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: A Global Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP) Agarwal, N. 4811 - Targeting T-Cell Lymphoma Using CD70-...
CML CP. Asciminib produced 92% complete hematologic remission (CHR); 54% CCyR, 48% durable MMR, including 57% MMR in patients deemed to have resistance to or unacceptable side effects from ponatinib, as well as 28% durable MMR in patients with a T315I mutation. Dose-limiting toxicities ...